NASDAQ
24.03.26 | 21:00
0,761 US-Dollar
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11:58 | Jefferies senkt Kursziel für TELA Bio wegen schwächerer Wachstumsaussichten | 2 | Investing.com Deutsch | ||
| 11:54 | Jefferies cuts TELA Bio stock price target on slower growth outlook | 2 | Investing.com | ||
| 00:18 | Tela Bio targets at least 8% revenue growth in 2026 while advancing commercial transformation | 1 | Seeking Alpha | ||
| Di | TELA Bio: Gewinn übertrifft Erwartungen, doch Umsatz enttäuscht - Aktie bricht ein | - | Investing.com Deutsch | ||
| Di | TELA Bio GAAP EPS of -$0.17 beats by $0.01, revenue of $20.9M misses by $0.14M | 2 | Seeking Alpha | ||
| Di | TELA Bio, Inc.: TELA Bio Reports Fourth Quarter and Full Year 2025 Financial Results | 131 | GlobeNewswire (Europe) | MALVERN, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today... ► Artikel lesen | |
| TELA BIO Aktie jetzt für 0€ handeln | |||||
| Fr | TELA Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.03. | TELA Bio, Inc.: TELA Bio to Announce Fourth Quarter and Full Year 2025 Financial Results | 2 | GlobeNewswire (USA) | ||
| 20.02. | TELA Bio, Inc.: TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 3 | GlobeNewswire (USA) | ||
| 23.01. | TELA Bio, Inc.: TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 3 | GlobeNewswire (USA) | ||
| 23.12.25 | BD faces hernia mesh lawsuit from Tela Bio | 7 | MassDevice | ||
| 23.12.25 | Small Medtech TELA Bio Takes On Becton Dickinson, Alleges Hernia Mesh Monopoly | 4 | Benzinga.com | ||
| 12.12.25 | TELA Bio, Inc.: TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 4 | GlobeNewswire (USA) | ||
| 01.12.25 | TELA Bio stock price target lowered to $3 by Lake Street on sales issues | 1 | Investing.com | ||
| 17.11.25 | TELA Bio, Inc.: TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 14.11.25 | TELA Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.11.25 | These Analysts Cut Their Forecasts On TELA Bio After Q3 Earnings | 1 | Benzinga.com | ||
| 14.11.25 | Piper Sandler lowers TELA Bio stock price target to $1.25 on soft Q3 results | 1 | Investing.com | ||
| 14.11.25 | TELA Bio stock price target lowered to $5 at Citizens on lower ASP | 1 | Investing.com | ||
| 14.11.25 | Tela Bio outlines at least 16% 2025 revenue growth target while strengthening commercial team and balance sheet | 1 | Seeking Alpha |
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MODERNA | 44,905 | +1,19 % | Moderna stands as the best performing large-cap healthcare stock YTD | ||
| SAREPTA THERAPEUTICS | 15,890 | +3,86 % | Sarepta Therapeutics: Positive Studiendaten zu Therapien für seltene Krankheiten stützen Aktie | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,176 | -1,49 % | Canaccord reiterates Pacific Biosciences stock rating on new chemistry | ||
| MYRIAD GENETICS | 3,980 | 0,00 % | Myriad Genetics, Inc.: Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer | SALT LAKE CITY, March 17, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that the U.S. Food and Drug... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 1,220 | 0,00 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces American Academy of Dermatology 2026 Presentation Featuring Clinical Study Results from Study of PH-762 for Cutaneous Carcinoma Underscoring Clinical Pipeline Advancement | King of Prussia, Pennsylvania--(Newsfile Corp. - March 23, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 3,754 | +2,40 % | Jefferies reiterates Buy rating on CytomX stock after phase 1 data | ||
| VIR BIOTECHNOLOGY | 8,570 | 0,00 % | Vir Biotechnology +70%: Deal-Überraschung mit Ansage | Die Aktie von Vir Biotechnology ist vorbörslich um rund 70 Prozent nach oben geschossen. Auslöser der Kursexplosion ist vor allem ein milliardenschwerer Kooperationsdeal mit dem japanischen Pharmakonzern... ► Artikel lesen | |
| TC BIOPHARM | 0,825 | 0,00 % | TC BioPharm plc - 15-12G, Securities registration termination | ||
| DAY ONE BIOPHARMACEUTICALS | 21,380 | +0,09 % | Weekly Buzz: Bristol Myers Squibb Wins FDA Nod; EU Okays Johnson & Johnson's AKEEGA; Ipsen Withdraws Tazverik, Day One Biopharmaceuticals Acquired | NEW BRUNSWICK (dpa-AFX) - This week's biotech landscape witnessed key FDA approvals, EU approvals, IND clearances, acquisitions, and clinical trial data readouts across key therapeutic areas... ► Artikel lesen | |
| ADMA BIOLOGICS | 11,330 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Addresses Misleading Short-Seller Report | RAMSEY, N.J. and BOCA RATON, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 30,640 | 0,00 % | Why Edgewise Therapeutics Stock Topped the Market on Tuesday | ||
| KINIKSA PHARMACEUTICALS | 44,940 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution | - ARCALYST- (rilonacept) Q4 2025 and full year 2025 net product revenue of $202.1 million and $677.6 million, respectively -- ARCALYST 2026 net product revenue expected to be $900 - $920 million... ► Artikel lesen | |
| ARCELLX | 114,66 | 0,00 % | Arcellx legt Zahlen vor - Augenmerk liegt auf Gilead-Übernahme | ||
| QIAGEN | 34,800 | +0,97 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 72,98 | 0,00 % | Morning Market Movers: urban-gro, WeShop Holdings, QVC Group, Apogee Therapeutics See Big Swings | OTTAWA (dpa-AFX) - At 8:30 a.m. ET on Monday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen |
TELA BIO INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,761 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TELA BIO INC finden Sie auf Wallstreet Online.